SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cold Genesys, Inc. Announces Agreement With FDA on Special Protocol Assessment of a Phase 2/3 Pivotal Trial ("BOND" Trial) of CG0070 as an Intravesical Treatment for Non-Muscle Invasive Bladder Cancer Patients With Carcinoma-In-Situ (Cis) or Cis With Ta and/or T1 Disease Who Have Failed BCG (“Bacillus Calmette-Guerin”) and Refused Cystectomy